Illumina, Inc. $ILMN Shares Sold by HighTower Advisors LLC

HighTower Advisors LLC lowered its holdings in shares of Illumina, Inc. (NASDAQ:ILMN) by 11.6% in the fourth quarter, Holdings Channel reports. The firm owned 40,031 shares of the life sciences company’s stock after selling 5,234 shares during the quarter. HighTower Advisors LLC’s holdings in Illumina were worth $5,250,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently bought and sold shares of the company. Elyxium Wealth LLC purchased a new position in Illumina during the 4th quarter worth $25,000. Board of the Pension Protection Fund purchased a new position in Illumina during the 4th quarter worth $26,000. Creative Capital Management Investments LLC raised its position in Illumina by 160.0% during the 4th quarter. Creative Capital Management Investments LLC now owns 195 shares of the life sciences company’s stock worth $26,000 after buying an additional 120 shares during the last quarter. TD Waterhouse Canada Inc. purchased a new position in Illumina during the 4th quarter worth $26,000. Finally, Laurel Wealth Advisors LLC purchased a new position in Illumina during the 4th quarter worth $26,000. Institutional investors and hedge funds own 89.42% of the company’s stock.

Illumina Stock Performance

Shares of ILMN opened at $158.70 on Friday. The company has a 50-day simple moving average of $132.92 and a 200-day simple moving average of $131.80. The company has a quick ratio of 1.36, a current ratio of 1.75 and a debt-to-equity ratio of 0.56. The company has a market capitalization of $24.01 billion, a PE ratio of 28.85, a P/E/G ratio of 2.49 and a beta of 1.42. Illumina, Inc. has a 52-week low of $78.79 and a 52-week high of $158.79.

Illumina (NASDAQ:ILMN) last announced its quarterly earnings results on Thursday, April 30th. The life sciences company reported $1.15 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.05 by $0.10. The business had revenue of $1.09 billion during the quarter, compared to the consensus estimate of $1.07 billion. Illumina had a net margin of 19.42% and a return on equity of 31.01%. The business’s revenue was up 4.8% compared to the same quarter last year. During the same quarter last year, the firm posted $0.97 EPS. Illumina has set its FY 2026 guidance at 5.150-5.300 EPS. Equities research analysts predict that Illumina, Inc. will post 5.2 earnings per share for the current fiscal year.

Illumina News Summary

Here are the key news stories impacting Illumina this week:

• Positive Sentiment: Illumina and SPT Labtech launched fireflyGO, a new automation platform designed to make targeted oncology research faster, simpler, and more scalable. The product is integrated with Illumina’s MiSeq i100 Series and could help broaden adoption of its sequencing workflow. Illumina and SPT Labtech unveil fireflyGO, enabling faster, simpler targeted oncology research
• Positive Sentiment: Illumina also introduced a distributed whole-genome sequencing solution for MRD research, expanding its oncology portfolio and making it easier for more labs to adopt molecular residual disease testing in clinical research. That supports the company’s long-term growth narrative in precision oncology. Illumina introduces the first distributed whole-genome sequencing solution for highly sensitive MRD research
• Neutral Sentiment: A separate marketwide report noted that the broader stock market reached fresh highs on upbeat macro news. While this may be helping overall sentiment, it is not specific to Illumina’s business. Dow Jones Futures: Stock Market Hits Highs On U.S.-Iran Deal; Dell Surges On Earnings
• Neutral Sentiment: One article flagged Illumina as a strong momentum stock, which may reinforce positive trader sentiment, but it did not include new fundamental information. Here’s Why Illumina (ILMN) is a Strong Momentum Stock

Insider Transactions at Illumina

In other Illumina news, Director Keith A. Meister sold 225,067 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The shares were sold at an average price of $145.55, for a total transaction of $32,758,501.85. Following the completion of the transaction, the director directly owned 3,604,441 shares in the company, valued at approximately $524,626,387.55. This trade represents a 5.88% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, SVP Christensen Jakob Wedel sold 700 shares of the firm’s stock in a transaction dated Wednesday, May 6th. The shares were sold at an average price of $139.04, for a total transaction of $97,328.00. Following the transaction, the senior vice president owned 15,056 shares of the company’s stock, valued at $2,093,386.24. This trade represents a 4.44% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 330,160 shares of company stock valued at $48,028,308 in the last quarter. Insiders own 2.90% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have commented on ILMN. Wall Street Zen downgraded shares of Illumina from a “strong-buy” rating to a “buy” rating in a research report on Saturday, May 9th. Robert W. Baird set a $137.00 price objective on shares of Illumina in a research report on Friday, February 6th. Barclays increased their price target on shares of Illumina from $110.00 to $122.00 and gave the company an “underweight” rating in a report on Friday, May 1st. Daiwa Securities Group upgraded shares of Illumina from a “neutral” rating to an “outperform” rating and set a $155.00 price target for the company in a report on Thursday, May 14th. Finally, Canaccord Genuity Group cut their price target on shares of Illumina from $150.00 to $140.00 and set a “hold” rating for the company in a report on Friday, May 1st. Seven equities research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Illumina currently has an average rating of “Hold” and an average target price of $137.75.

Illumina Profile

Illumina, Inc (NASDAQ: ILMN) is a global life sciences company that develops, manufactures and markets integrated systems for the analysis of genetic variation and function. Headquartered in San Diego, California and founded in 1998, Illumina offers a range of sequencing and array-based technologies used by academic researchers, clinical laboratories, pharmaceutical and biotechnology companies, consumer genomics firms and agricultural researchers to enable discovery, translational research and clinical applications.

The company’s product portfolio includes next-generation sequencing (NGS) platforms and associated consumables, microarrays for genotyping and methylation analysis, library preparation kits and targeted assays.